Finance
Markets
No recent trading data. The last price we hold for MRNA is from Jun 3 (48 days ago). This symbol may be delisted, renamed, or halted — the figures below reflect its last active session, not the current market.

MRNA

stock Healthcare Biotechnology
Moderna
$49.06 +3.42 (+7.49%) Delayed · quoted 47d ago
Concerning 40% Steady

What the indicators say

Mixed 4 of 5 trend signals bullish
Momentum · RSI 14 Neutral
52
0oversold 30overbought 70100

RSI 52 — momentum is balanced between buyers and sellers.

EMA 21 $48.17
Above
Near-term trend is up
SMA 50 $49.88
Below
Medium-term trend is down
SMA 200 $37.77
Above
Long-term trend is up
50 / 200-day
Golden cross
50-day above the 200-day — bullish
Supertrend $43.45
Uptrend
Price is holding above the Supertrend band — bullish

A mechanical reading of the chart’s indicators — not investment advice.

Key statsas of Jun 3

The day open and close within the day's range
Low $45.43 High $49.55
Open
$49.06
+7.49%
Close
$49.06
+7.49%
52-week range where the price sits across its year
52w low $22.28 52w high $59.55
Current
$49.06
Prev close
$45.64
Volume 0.93× the 3-month average
0 avg 2× avg
Today
6.75M
3-mo avg
7.30M

Earningscalendar synced from Yahoo 57d ago

Most recent
May 181 days ago
Next expected
Jul 31in 10 days

Recent earnings dates

  • May 1 81 days ago
  • Feb 13 158 days ago
  • Jan 12 190 days ago
  • Nov 6, 2025 257 days ago

Past earnings dates come from MRNA’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.

Fundamentalssynced from SEC 51d ago

Weak

Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), MRNA’s fundamentals read as weak overall.

P/E ratio No data
—

Earnings per share were negative, so a P/E cannot be formed; the company was unprofitable over the period.

Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.

Dividend yield Fair
0.00%

This company pays no dividend, common for firms reinvesting their profits back into growth.

The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.

Profit margin Weak
-145.2%

A -145.2% margin is thin; little of each revenue dollar survives as profit.

The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.

Return on equity Weak
-32.6%

A -32.6% return on equity is weak; owners' capital is barely being put to work.

Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.

Return on assets Weak
-22.9%

A -22.9% return on assets is low; the asset base is generating little profit.

Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.

Debt-to-equity Strong
0.43

At 0.43, the company carries less in liabilities than in equity, a conservative balance sheet.

Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.

Current ratio Strong
3.29

At 3.29, short-term assets comfortably cover short-term bills.

Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.

Revenue growth Weak
-39.9%

Revenue fell 39.9% from the prior year; the top line is contracting.

Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.

Earnings growth No data
—

The company was unprofitable in both years, so an earnings growth rate is not meaningful.

Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.

Financialssynced from SEC 51d ago

FY2021FY2022FY2023FY2024FY2025
Revenue $18.5B$19.3B$6.8B$3.2B$1.9B
Net income $12.2B$8.4B-$4.7B-$3.6B-$2.8B
Diluted EPS $28.29$20.12$-12.33$-9.28$-7.26
Dividend / share —————
Total assets $24.7B$25.9B$18.4B$14.1B$12.3B
Total liabilities $10.5B$6.7B$4.6B$3.2B$3.7B
Shareholder equity $14.1B$19.1B$13.9B$10.9B$8.7B

Leadershipsynced from SEC 55d ago

  • Hoge Stephen President
  • Afeyan Noubar Director
  • Horning Sandra Director
  • Hussain Abbas Director
  • Nabel Elizabeth G Director
  • Nader Francois Director
  • Rubenstein David M. Director
  • Tallett Elizabeth E Director

Officers and board are drawn from MRNA’s recent SEC ownership filings (Forms 3, 4 and 5).

Recent leadership changes

Notable recent eventspast year

  • May 8 +12.0% one-day move
  • Mar 4 +16.0% one-day move
  • Jan 21 +15.8% one-day move
  • Jan 13 +17.0% one-day move
  • Jan 6 +10.8% one-day move
  • Dec 31, 2025 FY2025 revenue −40% YoY
  • Dec 19, 2025 +9.2% one-day move
  • Dec 5, 2025 +8.7% one-day move
  • Nov 20, 2025 New 6-month low (-36% off peak)
  • Nov 20, 2025 −7.5% one-day move
  • Nov 3, 2025 −8.3% one-day move
  • Oct 30, 2025 +13.9% one-day move
  • Oct 1, 2025 +6.9% one-day move
  • Sep 12, 2025 New 6-month low (-32% off peak)
  • Sep 12, 2025 −7.4% one-day move
  • Jul 31, 2025 −8.1% one-day move

Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.

Recent SEC filingssynced from SEC 51d ago

© 2026 Isaac Bythewood · Some rights reserved